MedinCell to present at the Evercore ISI 2024 Emerging Biotech Conference
February 15, 2024
February 15, 2024
MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)
January 31, 2024
January 31, 2024
Teva announces recruitment completion of phase 3 clinical study of mdc-TJK
January 9, 2024
January 9, 2024
Jefferies initiates MedinCell’s coverage with a “Buy” recommendation
January 4, 2024
January 4, 2024
Half-Year results (April 2023 – September 2023)
December 19, 2023
December 19, 2023
MedinCell applauds Teva and Royalty Pharma collaboration to further accelerate olanzapine LAI program
November 13, 2023
November 13, 2023
MedinCell at the 2023 Jefferies Global Healthcare Conference -London, 14-16 November
November 6, 2023
November 6, 2023
MedinCell and the European Investment Bank (EIB) have replaced a financial covenant of their ongoing loan agreement to better fit with MedinCell business model
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
August 31, 2023
August 31, 2023
Participation terms in the Combined General Meeting
August 21, 2023
August 21, 2023
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
